Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies

SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in Q2 2026 with topline data expected in 2H 2027

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that key results from Phase I/II studies of LX2006 gene therapy in Friedreich ataxia (FA) have been , linked here.



JAMA Cardiology Publication

The assessment of safety and exploratory efficacy parameters of LX2006 combines data from two independent studies: nine participants from a Weill Cornell Medicine study, funded by the National Heart, Lung, and Blood Institute, and eight participants treated in the SUNRISE-FA study carried out by Lexeo Therapeutics. The two studies included patients with early cardiac disease and patients with established structural cardiac disease. In both studies, the patients received a one-hour intravenous infusion of LX2006 gene therapy and were evaluated from 6 to 36 months. Three different doses were tested among three cohorts of patients.